0001267565 false 0001267565 2020-07-08 2020-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 8, 2020



(Exact Name of Registrant as Specified in its Charter)


Virginia   001-37372   03-0416362
(State or Other Jurisdiction
of Incorporation or Organization)
  (Commission File Number)   (IRS Employer Identification


100 Technology Center Drive

Suite 300

Stoughton, MA 02072

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (781) 713-3699


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨







Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On July 8, 2020, David Hirsch, M.D., Ph.D. notified the Board of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”) that he would resign from the Board as a Class I director and all committees thereof, effective July 9, 2020, to devote his full time efforts to his other commitments; his resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. With best wishes, the Company thanks Dr. Hirsch for his dedicated service and valuable contribution as a member of the Board since February 2012.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: July 9, 2020 Collegium Pharmaceutical, Inc.
  By: /s/ Paul Brannelly
    Name: Paul Brannelly
    Title: Executive Vice President and Chief Financial Officer




Jul. 08, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 08, 2020
Entity File Number 001-37372
Entity Central Index Key 0001267565
Entity Tax Identification Number 03-0416362
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 100 Technology Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Stoughton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02072
City Area Code 781
Local Phone Number 713-3699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol COLL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false